Evidence map›Paper›PMID 40792123›Full record

ReviewGeneral psychiatry2025

The China Alzheimer Report 2025.

Nan Zhi, Rujing Ren, Jinlei Qi, Xinya Liu, Zike Yun, Shaohui Lin, Yisong Hu, Haixia Li, Xinyi Xie, Jintao Wang and 28 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in General psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Lecanemab use in Chinese patients with Alzheimer's disease: a 12-month multicenter real-world study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Observational
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Nan Zhi *Department of Neurology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0002-1854-0940
Rujing Ren *Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0009-0000-5941-4783
Jinlei Qi *Chronic Noncommunicable Disease Prevention and Control Center, Chinese Center for Disease Control and Prevention, Beijing, China.
Xinya Liu *School of Public Health, Fudan University, Shanghai, China.
Zike YunDepartment of Neurology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shaohui LinShanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yisong HuNational Survey Research Center, Renmin University of China, Beijing, China.
Haixia LiDepartment of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0002-4862-8302
Xinyi XieDepartment of Neurology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0009-0001-2678-1074
Jintao WangDepartment of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jianping LiDepartment of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0009-0002-2555-5742
Yikang ZhuShanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Mengyi GaoShanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Junjie YangShanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yiran WangShanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yurong JingSchool of Public Health, Fudan University, Shanghai, China.
Jieli GengDepartment of Neurology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0009-0004-0096-3402
Wenwei CaoDepartment of Neurology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0009-0009-0526-9926
Qun XuDepartment of Neurology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaoping YuDepartment of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuan ZhuDepartment of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ying ZhouNursing College, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lin WangNursing College, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chao GaoDepartment of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Binyin LiDepartment of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shengdi ChenDepartment of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Fang YuanDepartment of Neurology, Qilu Hospital of Shandong University (Qingdao), Qingdao, Shandong, China.
Ronghua DouDepartment of Neurology, Cangzhou Integrated Traditional Chinese and Western Medicine Hospital, Cangzhou, Hebei, China.
Xiaoyun LiuDepartment of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Xuena LiDepartment of Nuclear Medicine, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Yafu YinDepartment of Nuclear Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yan ChangDepartment of Nuclear Medicine, General Hospital of People's Liberation Army, Beijing, China.
Gang XuSchool of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yanting ZhongChronic Noncommunicable Disease Prevention and Control Center, Chinese Center for Disease Control and Prevention, Beijing, China.
Chunbo LiShanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0002-3387-4439
Ying WangSchool of Public Health, Fudan University, Shanghai, China.
Maigeng ZhouChronic Noncommunicable Disease Prevention and Control Center, Chinese Center for Disease Control and Prevention, Beijing, China.
Gang WangDepartment of Neurology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0001-6500-5863

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the sustained growth of the economy and significant changes in social demographics, the issue of elderly-related diseases has increasingly drawn attention, particularly. Alzheimer's disease (AD), as a representative disease of neurodegenerative diseases, has become a major challenge, affecting the health and quality of life of the elderly population severely. In recent years, the incidence, prevalence and mortality rates of AD have increased in China, imposing substantial economic burdens on families, society and the entire healthcare system. To proactively address this challenge and respond to the national 'Healthy China Action' initiative, leading experts from authoritative institutions jointly authored the China Alzheimer Report 2025. Building on previous editions, this report updates epidemiological data on AD in China, thoroughly analyses the latest economic burdens of the disease and comprehensively evaluates the current status of AD diagnosis and treatment services, as well as the allocation of public health resources in our country. Its release reflects China's progress in AD research and prevention, underscores societal concern for elderly health and aims to provide scientific guidance and data support for AD prevention, diagnosis and treatment. It also facilitates academic exchanges and cooperation, enhancing public awareness and promoting active participation in elderly healthcare, towards achieving 'healthy ageing' in China.

Indexed as

Cognition Disorders

Identifiers

PMID40792123
PMCPMC12336476

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.